Andrew Brunner
Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew Brunner as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 17:02 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04823624 · MBG453 in Lower Risk MDSMassachusetts General Hospital · terminated · Myelodysplastic Syndromes · principal investigator
- Ph2NCT03118466 · Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid LeukemiaMassachusetts General Hospital · completed · AML · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 17:02 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 17:02 UTC. The ranking covers the 200 most relevant of 37 PubMed records, and a shared surname and initials can bring in a namesake. All 37 on PubMed
- Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.Leukemia · 2021178 citationsRCR 8.8
- Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial.JAMA Oncol · 2021171 citationsRCR 13.1
- The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort.Blood Adv · 2018112 citationsRCR 4.1
- Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.Transpl Infect Dis · 201698 citationsRCR 3.8
- Results of universal ultrasound screening for developmental dysplasia of the hip: a prospective follow-up of 28 092 consecutive infants.Bone Joint J · 201875 citationsRCR 7.6
- A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.Am J Hematol · 202375 citationsRCR 7.1
- Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia.Am J Hematol · 201370 citationsRCR 2.0
- Comparison of 64-slice CT with gated SPECT for evaluation of left ventricular function.J Nucl Med · 200669 citationsRCR 2.1
- Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies.Blood Adv · 202261 citationsRCR 4.6
- Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.Clin Cancer Res · 202353 citationsRCR 5.1